Digging Up the Facts on Gilead Sciences, Inc. (GILD)

Adjust Comment Print

The Palisade Asset Management Llc holds 80,584 shares with $13.88M value, up from 74,488 last quarter.

The company declined -0.57% and closed its last trading session at $83.04. About shares traded. Gilead Sciences, Inc. It has underperformed by 24.43% the S&P500.

Argentiere Capital Ag decreased Gilead Sciences Inc (GILD) stake by 63.64% reported in 2017Q2 SEC filing. Ledyard National Bank sold 6,275 shares as Gilead Sciences Inc (GILD)'s stock declined 8.05%.

Lagoda Investment Management L.P. holds 4.27% of its portfolio in VolitionRX Ltd for 3.16 million shares. In order to determine directional movement, the 50-day and 200-day moving averages for Gilead Sciences, Inc. The fund owned 209,536 shares of the biopharmaceutical company's stock after selling 27,191 shares during the period. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since October 11, 2016 and is downtrending. It has underperformed by 18.60% the S&P500.

Analysts await Centurylink Inc (NYSE:CTL) to report earnings on October, 30. They expect $1.20 earnings per share, down 13.04% or $0.18 from last year's $1.38 per share. GILD's profit will be $2.70 billion for 9.86 P/E if the $2.07 EPS becomes a reality. Envestnet Asset Management Inc reported 0.12% of its portfolio in Gilead Sciences, Inc. Punch And Investment Mgmt Incorporated accumulated 1.69 million shares.

Brookstone Capital Management increased Ishares Tr (EMB) stake by 31,850 shares to 99,928 valued at $11.43 million in 2017Q2. Pepsico (NYSE:PEP) was raised too.

Among 17 analysts covering CIGNA (NYSE:CI), 15 have Buy rating, 0 Sell and 2 Hold. Equities analysts predict that Gilead Sciences will post $8.75 EPS for the current fiscal year. The firm earned "Buy" rating on Tuesday, October 25 by Jefferies. The company was upgraded on Wednesday, November 2 by BMO Capital Markets. Cantor Fitzgerald maintained Mylan N.V. (NASDAQ:MYL) on Wednesday, August 9 with "Hold" rating. Standpoint Research has "Buy" rating and $110 target. $460,313 worth of stock was sold by Hoeltzel Mary T on Wednesday, May 31. The firm has "Hold" rating given on Friday, July 14 by RBC Capital Markets. The firm has "Buy" rating given on Wednesday, July 19 by BMO Capital Markets. Us Savings Bank De has invested 0.01% in Centurylink Inc (NYSE:CTL). Its the same as in 2017Q1.

As of quarter end Addenda Capital Inc. had sold 3,427 shares trimming its position 3.7%. Global Thematic Prns Ltd Liability Corporation invested in 1.05M shares or 2.38% of the stock. Rhumbline Advisers holds 453,133 shares or 0.17% of its portfolio. Indiana & Management reported 0.21% in Amgen, Inc. Moreover, Southpoint Capital Advisors Lp has 0.11% invested in the company for 792,000 shares. Nfc Ltd has invested 0.08% in Merck & Co., Inc. It also upped Spdr Gold Trust (GLD) stake by 14,289 shares and now owns 52,802 shares.

Among 8 analysts covering Gilead Sciences (NDAQ:GILD), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. CIBC assumed coverage on Gilead Sciences in a research report on Thursday, October 5th.

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The rating was maintained by Piper Jaffray with "Overweight" on Friday, July 24. The firm has "Buy" rating given on Friday, April 29 by Citigroup. J P Morgan Chase & Co restated an overweight rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Tuesday, July 4th. (NASDAQ:GILD). 12,320 are held by Ledyard Bancorporation. On August 29 Credit Suisse made no change to the company rating of "Outperform" and lowered the price target from $95.00 to $85.00. The company was maintained on Thursday, March 23 by Jefferies. Mizuho maintained Gilead Sciences, Inc. They expect $2.07 EPS, down 23.33% or $0.63 from last year's $2.7 per share. PZN's profit will be $10.51 million for 19.75 P/E if the $0.15 EPS becomes a reality. After $2.51 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -17.53% negative EPS growth.

Since May 1, 2017, it had 0 buys, and 5 insider sales for $11.13 million activity. Insiders have sold a total of 486,819 shares of company stock worth $39,298,919 in the last ninety days. BidaskClub raised shares of Gilead Sciences from a "strong sell" rating to a "sell" rating in a report on Thursday, June 22nd. Its down 0.30, from 2.5 in 2017Q1.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Paradigm Financial Advisors LLC raised its holdings in shares of Gilead Sciences by 0.3% in the second quarter. (NASDAQ:CSPI). Renaissance Technology Lc owns 0% invested in CSP Inc. Acadian Asset Management Limited Liability Corporation has invested 0% in CSP Inc. (NASDAQ:GILD). Kempner Cap Mgmt reported 3.11% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 600 shares. The Nebraska-based Ameritas Inv Prtnrs has invested 0% in Old Line Bancshares, Inc. (NASDAQ:CSPI). Morgan Stanley invested in 0% or 3,471 shares. Waldron LP now owns 10,360 shares of the biopharmaceutical company's stock worth $711,000 after buying an additional 1,752 shares in the last quarter. Lincoln Corporation reported 7,103 shares. Hilltop stated it has 35,966 shares or 0.25% of all its holdings. Girard Ptnrs has invested 0.43% in Gilead Sciences, Inc. (NASDAQ:GILD) for 59,195 shares. (NYSE:MRK). Peak Asset Management Limited Liability Co owns 15,537 shares or 0.37% of their United States portfolio. Hussman Strategic Advsrs holds 0.39% in Gilead Sciences, Inc. Meyer Handelman Co. now owns 380,900 shares of the biopharmaceutical company's stock worth $25,871,000 after buying an additional 9,900 shares in the last quarter. Alabama-based Weiss Multi has invested 0.13% in Centurylink Inc (NYSE:CTL).